Plaintiffs must show that they will suffer particularized injury from rescheduling.
Region: DC
None of the plaintiffs showed either sufficient “injury” or “concrete harm” from the implementation of the CMS pilot program.
The letter states, “We respectfully request that you use your pardon power to commute the sentences to all those in the federal prison system serving non-violent marijuana-related offenses.”
“To clarify further, tetrahydrocannabinols produced through chemical conversion, even when hemp-derived, are considered synthetically produced for purposes of the Controlled Substances Act.”
Plaintiffs argue that the rescheduling order “exceeds the authority of the Attorney General under the CSA and is otherwise arbitrary and capricious.”
In a joint press release, the Treasury Department and the IRS said that they “expect DOJ’s action to have significant positive tax consequences for businesses in the medical marijuana industry.”
“Hemp-derived CBD has made a HUGE difference for so many people,” the President stated in a social media post.
Plaintiffs are seeking to permanently enjoin federal agencies from providing hemp-derived products to Medicare beneficiaries.